SAN DIEGO – March 18, 2013 — OncoSec Medical Inc. (OTCBB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers, announced Dr. Adil Daud, chair of OncoSec’s Melanoma Advisory Board, will present at the HemOnc Today Melanoma and Cutaneous Malignancies Meeting at the Hilton New York Hotel on Friday, March 22 at 2:25 PM ET.
Dr. Daud will provide a presentation titled “Gene Therapy in Melanoma with pIL-12” and will review previously announced Phase I and II data from the ImmunoPulse clinical program in melanoma. More information can be found here: http://www.hemonctodaymelanoma.com/agenda.aspx#Fri
About the HemOnc Today Melanoma Meeting
The HemOnc Today Melanoma Conference will feature more than 20 renowned speakers and 200 colleagues who will discuss pertinent aspects of management and biology of melanoma and other cutaneous malignancies.
The two-day event will feature expert perspectives from renowned specialists who have advanced expertise in oncology, dermatology and cutaneous malignancies and will explain how you can apply the new research and advances presented to your own patients and practice.
North America is home to some incredible conferences and conventions surrounding cancer research, therapy development and biotech investments. With the strength of the American biotech and life sciences industries, several of these lineage conferences have been around for decades. Many CEOs, scientists and clinical experts speak at the various events and chair panels to create discussions on various topics that are currently of large importance in medicine. Each quarter, we attend or keep our eye on at least a few of these events. For March and April, these are 4 of the upcoming conferences that we are interested in:
As one of the cancer types that we at OncoSec concentrate on, we are constantly involved in not only developing an alternative treatment for melanoma but also evaluating the public and professional knowledge base surrounding the development, prevention and awareness of the disease. As a company directly involved in the research side, we are constantly inundated with statistics and methods. However, much of the general public is still unaware of the potentially deadly consequences of melanoma. Perhaps it is due to the relatively small size of moles, an increase in survival rates or the predominance of tanning but something in our culture needs a serious shift, if we are going to collectively work towards better preventative measures.
There are many factors that can influence the risk of cancer in an individual. Whether it is sunburns and melanoma, smoking and the lungs, or nitrates and the kidneys/pancreas, there are many human activities that are known to increase the risk of cancer. Cancer symptoms and warning signs may not always be apparent: it’s one of the reasons many cancers are often not caught at an early stage. Without exams and screenings, cancer can often develop into a late stage, before signs become apparent. It is because of this that awareness around exams and screenings is so important.
Autoimmune diseases are a type of condition in which the body’s immune system begins to attack and terminate healthy cells and tissues within the body. In a properly functioning immune system, white blood cells protect the body from foreign agents such as bacteria and viruses, through producing antibodies to locate and destroy them. However, in autoimmune disease patients, the body is unable to differentiate between healthy cells and attacking viral or bacterial agents. This results in white bloods cells indiscriminately destroying any other types of cells.
From time to time, different diseases and viruses see an increase in cases. It is important to know which ailments may be on the rise, in order to aid in prevention and awareness. While some countries may experience outbreaks that are dissimilar to other areas around the world, some are prevalent internationally. We’ve compiled a list of 4 that have had a recent global impact but especially in America:
The point at which cancer is discovered in the body can make a large impact on successful treatment. However, different types of cancer can be discovered much more easily than others. While many types of cancers form inside the body and are much harder to detect – with the naked eye – there are some that start on the skin or exterior of the body and are easy to see. Having regular check-ups – and being screened for cancer, at the first sign of a problem – will make all the difference.
Presentations on December 6 to Cover ImmunoPulse Therapy and Phase II Study of Melanoma Patients
SAN DIEGO – December 04, 2012 — OncoSec Medical Inc. (OTCBB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers, announced it will be presenting at the DNA Vaccines 2012 Conference at the Loews Coronado Bay Resort in San Diego, California. OncoSec is a Silver Sponsor of the conference.
The Company will conduct two presentations within the Cancer Immune Therapy Track on Thursday, December 6:
From 11:30 AM-12:00 PM PT, Richard Heller, Ph.D., director of the Frank Reidy Research Center for Bioelectrics at Old Dominion University, will speak on “Gene Electrotransfer for the Enhanced Delivery of Immunomodulating Agents.” In this presentation, Dr. Heller will present data on electroporation and delivery of plasmids for cancer immunotherapy, a technology used in OncoSec’s ImmunoPulse therapy.
From 12:00 PM-12:30 PM PT, Adil Daud, M.D., clinical professor of medicine and dermatology and director of the melanoma program at the University of California, San Francisco, will speak on “Clinical Studies of Melanoma Therapy.” In this presentation, Dr. Daud will be reviewing previously presented interim data from OncoSec’s ongoing Phase II trial for metastatic melanoma for which he is principal investigator.
The DNA Vaccines Conference brings in an array of researchers from all corners of the world to present new cutting-edge discoveries in DNA vaccines that have never before been presented or published at any other meeting. For more information about the conference, please visit: www.bioconferences.com/conferences/dna/index.aspx